Cargando…

Targeting mTOR in Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic disorder and constitutes approximately 25% of cancer diagnoses among children and teenagers. Pediatric patients have a favourable prognosis, with 5-years overall survival rates near 90%, while adult ALL still correlates with poorer surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Melloni, Elisabetta, Neri, Luca M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406494/ https://www.ncbi.nlm.nih.gov/pubmed/30795552 http://dx.doi.org/10.3390/cells8020190

Ejemplares similares

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments
por: Simioni, Carolina, et al.
Publicado: (2018)

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
por: Simioni, Carolina, et al.
Publicado: (2015)

Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
por: Buono, Roberta, et al.
Publicado: (2023)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

The role of the mTOR pathway in diabetic retinopathy
por: Casciano, Fabio, et al.
Publicado: (2022)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
por: Ultimo, Simona, et al.
Publicado: (2017)

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)
por: Nemes, Karolina, et al.
Publicado: (2013)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
por: Chang, Yoon Soo, et al.
Publicado: (2023)

The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies
por: Simioni, Carolina, et al.
Publicado: (2021)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells
por: Silic-Benussi, Micol, et al.
Publicado: (2022)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
por: Guo, Naxin, et al.
Publicado: (2019)

Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging
por: Simioni, Carolina, et al.
Publicado: (2018)

Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
por: Folgiero, Valentina, et al.
Publicado: (2016)

The Cutting Edge: The Role of mTOR Signaling in Laminopathies
por: Chiarini, Francesca, et al.
Publicado: (2019)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Potential efficacy and prognosis of silencing the CRLF2-mediated AKT/mTOR pathway in pediatric acute B-cell lymphoblastic leukemia
por: Jiang, Min, et al.
Publicado: (2019)

Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lrrl6k4jiir76sncikiithp1nr